Anand Sharma to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Anand Sharma has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
2.809
-
Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers. In Vivo. 2020 Nov-Dec; 34(6):3675-3679.
Score: 0.569
-
A rare occurrence of biphasic pulmonary blastoma in an elderly male. Anticancer Res. 2013 Sep; 33(9):3911-5.
Score: 0.346
-
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. 2011 Mar; 41(3):334-42.
Score: 0.285
-
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
Score: 0.283
-
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
Score: 0.279
-
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Score: 0.270
-
Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13.
Score: 0.249
-
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 02; 23(2):259-269.
Score: 0.154
-
Somatic Transformation in Metastatic Testicular Germ Cell Tumours - A Different Disease Entity. Anticancer Res. 2019 Sep; 39(9):4911-4916.
Score: 0.131
-
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013 Apr 10; 31(11):1415-21.
Score: 0.084
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.075
-
Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):543-9.
Score: 0.069
-
Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.
Score: 0.015